TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35133982
Drug: Chemotherapy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy without CIPN
Study: 35134259
Drug: Avatrombopag 40
Normalized name: avatrombopag 40 MG Daily Dose, 20 MG Oral Tablet 10 Count Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avatrombopag 40 mg
Study: 35134259
Drug: Avatrombopag 60
Normalized name: avatrombopag 60 MG Daily Dose, 20 MG Oral Tablet 15 Count Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avatrombopag 60 mg
Study: 35134880
Drug: Ibezapolstat 450
Normalized name: Ibezapolstat
DrugBank: Ibezapolstat (DB16189)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibezapolstat 450 mg orally every 12 hours for 10 days
Study: 35135499
Drug: Booklet-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booklet-based intervention for diabetic hypoglycaemia (Hypos can strike twice)
Study: 35135700
Drug: MMR vaccination
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR vaccination (two doses)
Study: 35135832
Drug: Inactivated SARS-CoV-2
Normalized name: Inactivated SARS-Cov-2 Vaccine
DrugBank: Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences) (DB15863)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated SARS-CoV-2 vaccine (CoronaVac)
Study: 35135832
Drug: Prednisone >7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone >7.5 mg/day
Study: 35136603
Drug: Autologous chimeric
Normalized name: Autologous chimeric antigen receptor (CAR) T cells targeting B7-H3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous chimeric antigen receptor (CAR) αβ T-cell therapies
Study: 35137142
Drug: Suppressed adrenocorticotropic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppressed adrenocorticotropic hormone (≤2.2 pmol/L)
Study: 35137228
Drug: ONC201 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ONC201 treatment
Study: 35137627
Drug: Low-dose sublingual
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose sublingual fentanyl
Study: 35137871
Drug: ELMOcpap system
Approvals — FDA: no, EMA: no, PMDA: no
Description: ELMOcpap system (CPAP via ELMO interface with oxygen and compressed air flow meters at 30 L/min each, PEEP valve, CPAP levels = 8-10 cmH2O)
Study: 35137871
Drug: ELMOcpap system
Approvals — FDA: no, EMA: no, PMDA: no
Description: ELMOcpap system (CPAP at 10 cmH2O, total gas flow of 56-60 L/min)
Study: 35138325
Drug: Sequential algorithm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential algorithm using 3-D LVEF, GLS, and GCS
Study: 35138442
Drug: Appropriate DOAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Appropriate DOAC dosage
Study: 35138442
Drug: Inappropriate DOAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inappropriate DOAC dosage
Study: 35138442
Drug: Survival comparison
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Survival comparison between underdosage and appropriate dosage
Study: 35138529
Drug: Afatinib plus
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Afatinib plus vinorelbine 25 mg/m
Study: 35138529
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (afatinib plus vinorelbine or paclitaxel)
Study: 35138919
Drug: Taselisib monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taselisib monotherapy
Study: 35139911
Drug: Systematic electronic
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic electronic screening for substance use and mental health symptoms via secure messaging and clinic-based tablets, integrated into the electronic health record (EHR).
Study: 35139911
Drug: Multiple methods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple methods of questionnaire completion (secure messaging and clinic-based tablets).
Study: 35140147
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PHI and MRI findings
Study: 35141162
Drug: GAD-M regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAD-M regimen (Gemcitabine, Peg-Asparaginase, Dexamethasone, Methotrexate) administered for 6 cycles
Study: 35144847
Drug: MenACYW-TT conjugate
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MenACYW-TT conjugate vaccine co-administered with routine pediatric vaccines (DTaP-IPV/Hib, PCV7/PCV13, MMR, and varicella)
Study: 35144847
Drug: MenACYW-TT conjugate
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MenACYW-TT conjugate vaccine
Study: 35144847
Drug: Routine pediatric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine pediatric vaccines
Study: 35144953
Drug: 4 weeks
Normalized name: risperiDONE 75 mg/4 weeks intramuscular powder for injection, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 weeks of daily iTBS treatment of left DLPFC
Study: 35144989
Drug: Add-on inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on inhaled budesonide
Study: 35145218
Drug: Sipuleucel-T (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sipuleucel-T (3 infusions)
Study: 35146939
Drug: Infusional gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusional gemcitabine (100 mg/m) with concurrent radiotherapy (50.4-54 Gy over 28 days)
Study: 35148720
Drug: Standard provider-initiated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard provider-initiated testing using rapid antibody tests
Study: 35149207
Drug: Arterial stiffness
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arterial stiffness (pulse wave velocity measures: carotid-femoral, femoral-foot, carotid-radial, augmentation index, brachial distensibility)
Study: 35149591
Drug: VCN-01 administered
Normalized name: VCN-01
DrugBank: VCN-01 (DB18193)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VCN-01 administered intratumorally at doses up to 1×10,
Study: 35149591
Drug: VCN-01 combined
Normalized name: VCN-01
DrugBank: VCN-01 (DB18193)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VCN-01 combined with standard chemotherapy,
Study: 35149641
Drug: Ledipasvir-sofosbuvir (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ledipasvir-sofosbuvir (90 mg/400 mg) once daily for 12 weeks
Study: 35150293
Drug: Low-dose dobutamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dobutamine (LDD) stress test at 10 µg/kg/min
Study: 35150293
Drug: Low-dose dobutamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dobutamine (LDD) stress test at 5, 10, 15 µg/kg/min
Study: 35150293
Drug: Low-dose dobutamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dobutamine (LDD) stress test
Study: 35150296
Drug: 90-yttrium-ibritumomab tiuxetan
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90-yttrium-ibritumomab tiuxetan (90Y-IT) as first-line treatment
Study: 35150356
Drug: M3541 (50-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: M3541 (50-300 mg administered on RT fraction days)
Study: 35150355
Drug: Sequential postural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential postural recruitment maneuver
Study: 35151024
Drug: Healthcare provider
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Healthcare provider education and prescription drug monitoring programs
Study: 35151262
Drug: 2-axis turntable
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-axis turntable based BPPV treatment
Study: 35151262
Drug: Regular testing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular testing for BPPV and treatment with appropriate liberation maneuvers
Study: 35151268
Drug: Diosmectite (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diosmectite (3 g/sachet, 3 sachets/day)
Study: 35151584
Drug: Atezolizumab (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (1200 mg IV infusion every 3 weeks) plus Tazemetostat (800 mg orally BID on days 1 to 21)
Study: 35152295
Drug: CMV viremia
Normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMV viremia ≥ 1000 IU/mL in HEU children
Study: 35153091
Drug: Plant-derived PA83-FhCMB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant-derived PA83-FhCMB vaccine at doses of 12.5, 25, 50, or 100 µg with Alhydrogel®
Study: 35153091
Drug: Plant-derived PA83-FhCMB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant-derived PA83-FhCMB vaccine
Study: 35154390
Drug: Pharyngeal electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharyngeal electrical stimulation (PES) for 10 minutes, 3 consecutive days in addition to Standard Logopaedic Therapy (SLT)
Study: 35154390
Drug: Standard Logopaedic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Logopaedic Therapy (SLT) alone
Study: 35154704
Drug: Standard systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard systemic treatment for mCRC
Study: 35154830
Drug: MRI-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI-based treatment plans
Study: 35154830
Drug: CT-based treatment
Normalized name: Ct-053 free base
DrugBank: Ningetinib (DB16256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-based treatment plans
Study: 35155599
Drug: Loop diuretic
Normalized name: Loop diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loop diuretic treatment
Study: 35155859
Drug: IONIS-FXI, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: IONIS-FXI, 300 mg open-label dose
Study: 35155863
Drug: HCV D-RNA-positive/R-negative
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV D-RNA-positive/R-negative kidney transplantation (KT) followed by 8 weeks of glecaprevir/pibrentasvir (G/P) initiated 2 to 5 days post-KT
Study: 35156036
Drug: Osimertinib 80
Normalized name: osimertinib 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib 80 mg daily (arm A)
Study: 35156036
Drug: Osimertinib 80
Normalized name: osimertinib 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib 80 mg daily (arm B)
Study: 35156036
Drug: Osimertinib 80
Normalized name: osimertinib 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib 80 mg daily (arm C)
Study: 35156036
Drug: Osimertinib dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib dose escalation to 160 mg
Study: 35156068
Drug: GX-19 (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: GX-19 (1.5 mg)
Study: 35156068
Drug: GX-19 (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: GX-19 (3.0 mg)
Study: 35156068
Drug: GX-19N (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: GX-19N (3.0 mg)
Study: 35156195
Drug: Repeat dosing
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat dosing of liso-cel
Study: 35156500
Drug: Coach-guided videoconferencing
Normalized name: coachwhip stem extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coach-guided videoconferencing acceptance and commitment therapy (ACT) with psychoeducation
Study: 35156519
Drug: Targeted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted therapy with autophagy inhibition
Study: 35156519
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving standard targeted therapy without autophagy inhibition
Study: 35156709
Drug: Anti-spike antibody
Normalized name: spike lavender oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-spike antibody titres
Study: 35157769
Drug: Recombinant zoster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant zoster vaccine (RZV) in treatment naïve (TN) CLL patients
Study: 35157769
Drug: Recombinant zoster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant zoster vaccine (RZV) in patients receiving BTKi therapy
Study: 35157978
Drug: Durvalumab (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (1500 mg every 28 days) with Cetuximab and Radiotherapy
Study: 35157988
Drug: Machine Learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine Learning (ML) models using random survival forest (RSF) method
Study: 35158476
Drug: Cladribine tablets
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cladribine tablets 3.5 mg/kg over 2 years
Study: 35159082
Drug: Androgen-deprivation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen-deprivation therapy (ADT) + Docetaxel
Study: 35159082
Drug: Androgen-deprivation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen-deprivation therapy (ADT) - Docetaxel
Study: 35162827
Drug: ReStoreD intervention
Normalized name: Restone
Approvals — FDA: no, EMA: no, PMDA: no
Description: ReStoreD intervention (8-week remotely administered dyadic intervention)
Study: 35164584
Drug: Surrogates' belief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surrogates' belief in the necessity of all medications
Study: 35164584
Drug: Patients' perception
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients' perception of medication burden
Study: 35164745
Drug: Statins, ACE-I,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statins, ACE-I, ARBs, diabetes medications
Study: 35164745
Drug: Absence of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absence of treatment
Study: 35164860
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of plasma Aβ and gut microbiota
Study: 35164933
Drug: No Proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Proton Pump Inhibitors (Control)
Study: 35165103
Drug: Health-related quality
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health-related quality of life (HRQoL) assessed using the Functional Assessment of Cancer Therapy-Lung (FACT-L) at baseline and at the end of the first cycle of chemotherapy.
Study: 35165236
Drug: Cognitive Orientation
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Orientation to daily Occupational Performance (knowledge translation intervention)
Study: 35165421
Drug: Updated mRNA
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Updated mRNA vaccine against the SARS-CoV-2 Omicron variant
Study: 35166929
Drug: Surufatinib 250
Normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surufatinib 250 mg QD plus toripalimab 240 mg Q3W
Study: 35167031
Drug: Intravenous posaconazole
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous posaconazole 300 mg twice on day 1, then 300 mg once daily on days 2-10, and either 300 mg once daily or oral suspension 200 mg 3 times daily for up to 18 days for a maximum of 28 days.
Study: 35167031
Drug: Intravenous posaconazole
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous posaconazole (intensive PK group)
Study: 35167031
Drug: Intravenous posaconazole
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous posaconazole (sparse PK group)
Study: 35167051
Drug: Liraglutide (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (1.2 mg/day) as an add-on to metformin for 18 months
Study: 38423992
Drug: Avacopan 30
Normalized name: Avacopan
DrugBank: Avacopan (DB15011)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avacopan 30 mg twice daily
Study: 35167187
Drug: Prednisone on
Normalized name: Prednisone only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone on a tapering schedule
Study: 35167329
Drug: Adagrasib 600
Normalized name: Adagrasib
DrugBank: Adagrasib (DB15568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adagrasib 600 mg twice a day
Study: 35167586
Drug: PWUD with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PWUD with TB disease who smoke illicit drugs
Study: 35167972
Drug: Drug-free remission
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug-free remission at 5 years
Study: 35168547
Drug: Rituximab 1000
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 1000 mg on days -14 and -7, followed by gemcitabine/cisplatin every 3 weeks, and rituximab every 6 months thereafter (Protocol 1)
Study: 35168547
Drug: Rituximab 375
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 375 mg/m2 concomitantly with gemcitabine/cisplatin (Protocol 2)
Study: 35168605
Drug: Asprosin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asprosin treatment in HUVECs
Study: 35169140
Drug: Treated with
Normalized name: Autologous ex vivo expanded cd4+-enriched leukocytes treated with the de-methylating agent 5-aza-deoxycytidine
DrugBank: Autologous ex vivo expanded cd4+-enriched leukocytes treated with the de-methylating agent 5-aza-deoxycytidine (DB19219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treated with prednisone and/or antibiotics in the outpatient setting
Study: 37164959
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of NDV-HXP-S vaccine
Study: 37164959
Drug: Intranasal followed
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal followed by intramuscular administration of NDV-HXP-S vaccine
Study: 35171350
Drug: Cabozantinib and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib and panitumumab combination therapy
Study: 35171658
Drug: Sapanisertib 30
Normalized name: SAPANISERTIB
DrugBank: Sapanisertib (DB11836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sapanisertib 30 mg by mouth once weekly
Study: 35171913
Drug: P2Y12 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: P2Y12 inhibitors (duration: 12 months)
Study: 35171913
Drug: Permanent discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permanent discontinuation of P2Y12 inhibitors
Study: 35172719
Drug: Therapeutic exercise
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic exercise as a treatment for chronic low back pain
Study: 35172719
Drug: Biomedical model
Normalized name: hypromellose
DrugBank: Hypromellose (DB11075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biomedical model of treatment
Study: 35174078
Drug: Primary tumor
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary tumor resection (PTR) after induction chemotherapy with XELOX or mFOLFOX6
Study: 35174078
Drug: Chemotherapy-alone (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy-alone (no PTR)
Study: 35174749
Drug: Machine learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine learning (ML) techniques for identifying clinical phenotypes of T2D
Study: 35175229
Drug: Semaglutide injection
Normalized name: semaglutide Injectable Product
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Semaglutide injection at 2.4 mg once weekly
Study: 35175355
Drug: VSV-IFNβ-NIS (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: VSV-IFNβ-NIS (1 single IV dose at DL1, DL2, DL3, and DL4)
Study: 35175355
Drug: VSV-IFNβ-NIS (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: VSV-IFNβ-NIS (1 single IV dose at DL4)
Study: 35175355
Drug: VSV-IFNβ-NIS (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: VSV-IFNβ-NIS (1 single IV dose across all dose levels)
Study: 35175381
Drug: Unimodal ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unimodal ultrasound ML algorithms
Study: 35175381
Drug: Multi-modal ultrasound
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-modal ultrasound ML algorithms
Study: 35176457
Drug: Pemigatinib 1-20
Normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pemigatinib 1-20 mg once daily intermittently (2 weeks on/1 week off; n = 70) or continuously (n = 58)
Study: 35177038
Drug: Asthma control
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Asthma control and oral corticosteroid use patterns
Study: 35177299
Drug: J&J vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: J&J vaccine
Study: 35177415
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of tumor-infiltrating lymphocytes (TILs) after modified lymphodepleting regimen
Study: 35177415
Drug: Modified lymphodepleting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified lymphodepleting regimen including intravenous cyclophosphamide (20 mg/kg for 3 days) and half dosage (100 mg) of PD1 antibody
Study: 35177453
Drug: Initial non-operative
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial non-operative treatment (intravenous antibiotics with or without percutaneous drainage) for children with appendiceal mass and/or abscess
Study: 35178092
Drug: Implant follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant follow-up for a mean duration of 7.22 years
Study: 35178092
Drug: Implant characteristics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant characteristics including location, bone level, and number
Study: 35178092
Drug: Clinical peri-implant
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical peri-implant and periodontal soft tissue statuses
Study: 35178092
Drug: Peri-implant parameters
Normalized name: casanthranol / docusate sodium Oral Capsule [Peri-Colace]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peri-implant parameters